Rituxan regulatory update

The U.K.'s NICE issued guidance recommending use of Roche's MabThera rituximab in combination with fludarabine and cyclophosphamide to treat relapsed or refractory chronic lymphocytic leukemia (CLL) except in patients who have not previously responded to fludarabine or have relapsed within 6 months of treatment or have previously been treated with MabThera. The guidance is in line with a March FAD but also recommends the combination in patients who previously received MabThera in a clinical trial (see BioCentury, March 8). ...